Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

פריטים דומים

• Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
  מאת: Cadegiani, Flavio A., et al.
  יצא לאור: (2020)
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated
  מאת: Wambier, Carlos Gustavo, et al.
  יצא לאור: (2020)
• Use of Spironolactone in SARS-CoV-2 ARDS Patients
  מאת: Dumanlı, Güleren Yartaş, et al.
  יצא לאור: (2020)
• SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study
  מאת: Nguyen, Cristina, et al.
  יצא לאור: (2021)
• Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
  מאת: Cadegiani, Flávio A.
  יצא לאור: (2020)